Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

10
Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?

2h zacks
Launched on 10/31/2014, the ARK Genomic Revolution Multi-Sector ETF (ARKG - Free Report) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Broad segment of the equity market.
NTLA ARKG NVTA FSTA FMAT ILMN ARKK

47
Invitae May Become The Amazon Of Genetics - And It's Happening Faster Than Expected

2018-08-14 seekingalpha
The company is set to hit over $500 million in revenue by the end of 2020 with 50% gross margins and a market cap today of $750M.
FB NVTA AMZN GOOGL AAPL GOOG ILMN

24
Week 33 Breakout Forecast: Short-Term Picks To Give You An Edge

2018-08-13 seekingalpha - 3
Publishing 2 of the 8 new Week 32 breakout stocks that are available only to subscribers with better than 10% short-term upside potential.
SMRT NVTA NFEC EXPI SHSP PACB

6
NVTA / Invitae Corp. S-3

2018-08-10 sec.gov
S-3 Table of Contents As filed with the Securities and Exchange Commission on August 9, 2018 Registration No. 333- NVTA

6
NVTA / Invitae Corp. 10-Q (Quarterly Report)

2018-08-09 sec.gov
nvta-10q_20180630.htm UNITED STATES
NVTA

6
Invitae: Growth Continues Unabated

2018-08-09 seekingalpha
Today, in the spotlight is genetic testing concern Invitae, an 'off the radar' small cap stock.
NVTA

6
Invitae's (NVTA) CEO Sean George on Q2 2018 Results - Earnings Call Transcript

2018-08-08 seekingalpha
Good afternoon. My name is Christina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Invitae Second Quarter 2018 Financial Results Conference Call. [Operator Instructions]
NVTA

7
Invitae (NVTA) Reports Q2 Loss, Tops Revenue Estimates

2018-08-08 zacks
Invitae (NVTA - Free Report) just came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.66 per share a year ago. These figures are adjusted for non-recurring items.
NVTA KRO CIVI SBOW

6
NVTA / Invitae Corp. 8-K (Current Report)

2018-08-08 sec.gov
nvta-8k_20180807.htm UNITED STATES
NVTA

11
Cerner (CERN) Looks Good: Stock Adds 6.2% in Session

2018-08-06 zacks
Cerner Corporation (CERN - Free Report) was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the near-flat trend of $60.24 –$63.71 in the past one month time frame.
NVTA CERN EFR UUUU BGSF FUN

12
Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?

2018-07-27 zacks - 1
Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the ARK Genomic Revolution Multi-Sector ETF (ARKG - Free Report) , a passively managed exchange traded fund launched on 10/31/2014.
NTLA ARKG NVTA NVR ILMN TRN ARKK

7
Invitae (NVTA): Moving Average Crossover Alert

2018-07-26 zacks - 1
Invitae Corporation (NVTA - Free Report) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for NVTA broke out above the 200 Day Simple Moving Average, suggesting a short-term bullish trend.
NVTA

24
NVTA / Invitae Corp. 8-K (Current Report)

2018-06-29 sec.gov - 6
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
NVTA

24
NVTA / Invitae Corp. 8-K (Current Report)

2018-06-12 sec.gov - 6
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
NVTA

45
Eidos Therapeutics IPO: Phase 2 Results In 2018, And 30% In Cash Per Share

2018-06-12 seekingalpha - 1
Investors only checking the balance sheet will not notice $48 million from the conversion of convertible preferred stock.
SHPG BHVN NVTA LXRX AKCA CHRS

Related Articles

REPH: Recro Pharma Analysis and Research Report

10h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

11h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

11h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 46185L103